FDA's One-Day Inspectional Assessments: Continuous Readiness Replaces Cycle Prep

A Quiet Pilot With Loud Implications

On May 6, 2026, the FDA announced that it has been piloting one-day inspectional assessments since April. The agency had already completed approximately 46 of these as of late April, most ending in No Action Indicated outcomes.

The phrasing in the announcement is careful. These are described as "shorter, focused screening assessments to complement standard FDA inspections." They are explicitly not replacements for full inspections. The pilot does not apply to higher-risk facilities. Investigators retain authority to expand the scope or duration if warranted.

But read past the careful phrasing and the picture is clear: the agency is moving from periodic deep inspections to a continuous-coverage model. And the documentation expectations that follow from that shift are not the documentation expectations most regulatory operations teams currently plan around.

The Old Rhythm

For most sponsors, inspection prep has had a rhythm. You knew roughly when an inspection might come. You had time to assemble batch records, validation packages, training documentation, and SOPs into something an investigator could be walked through. The week before the inspection was a sprint. The week of the inspection was tightly choreographed. After the inspection closed, the team relaxed and the documentation drifted back to its working state until the next cycle.

That rhythm assumed two things. First, that inspections were rare enough to make sprint prep worth it. Second, that the gap between sprint state and steady state was tolerable because no one was watching during the gap.

The one-day assessment pilot breaks both assumptions.

If 46 short assessments happened in roughly six weeks across multiple FDA inspectorates, the per-facility probability of being touched in any given quarter has gone up. Not dramatically, not yet — but enough that the planning model needs to shift.

And because these are shorter and more focused, they are exactly the kind of inspection where documentation that was assembled for an inspection cycle, then allowed to drift, will not look the same as documentation that has been kept current. The investigator is in and out. The signal they are looking for is "is this facility's documentation a routine artifact of operations, or is it a special-purpose package?"

What the Pilot Is Actually Optimising For

The FDA was unusually transparent about what they want out of this pilot. Three things.

Broader surveillance coverage. They can hit more facilities with the same investigator-hours. Risk models get more data points. Lower-risk facilities get touched more often, even if briefly.

Risk model inputs. Recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations all get harvested as data that feeds the next-cycle inspection plan.

Industry feedback signal. "Timely feedback while minimising operational disruption, particularly for lower-risk establishments." Translation: the agency wants to give industry a partial-credit signal before issues accumulate to the point where a full inspection finds a 483.

The first two of these have implications for how documentation needs to be prepared. The third has implications for how the documentation strategy should shift.

The Continuous-Readiness Documentation Stack

What does documentation that holds up cold look like?

It is documentation where the version under inspection is the version that was actually used in operations, not a curated version assembled for the inspector. The investigator can ask "show me the batch record for this lot" and the system that surfaces the record is the same system the QC team uses every day, not a separate inspection-prep folder.

It is documentation where cross-references resolve in real time. If an SOP references a validation package, the validation package is one click away and is the current version. If a batch record references a deviation, the deviation is closed (or open with a clear status) and the linked CAPA is current.

It is documentation where training records, supplier qualifications, and equipment validations are all synchronised against the same operational events. When an investigator asks why operator X performed step Y, the answer comes from the training matrix that's tied to the same operational system that recorded the step.

The teams that have this in place will pass one-day assessments with NAI outcomes the way the FDA's pilot data already shows most facilities are passing. The teams that have a sprint-prep documentation model will get caught short, because the sprint window has effectively been removed.

What This Means for Regulatory Writing Teams

Most of the immediate operational changes here land on QA and manufacturing operations, not on regulatory writing. But the writing teams have a derivative exposure that is worth thinking through.

The CMC sections of submissions, the periodic safety updates, and any document that references manufacturing facilities or quality systems all carry an implicit assumption that the operational documentation behind those sections is current and consistent. When inspection patterns change, the freshness of the supporting documentation changes. The writing team's job is to make sure the submission narrative does not run ahead of the operational state.

In practice, that means the regulatory writing function needs a tighter feedback loop with operations than most teams have today. Not weekly status meetings — direct read access to the systems that record what is actually happening on the floor, in the lab, and in the QC suite. The submission is supposed to describe a real state of operations. Continuous-coverage inspections increase the cost of any drift between what is described and what is observable.

The Pilot Will Not Stay a Pilot

The FDA was explicit that the one-day pilot will continue through fiscal year 2026, with additional assessments planned across inspectorates. The agency is developing evaluation metrics for inspection duration, escalation rates, and the utility of findings.

That language describes a pilot that will be evaluated against quantitative criteria and, if it meets them, will be expanded. The agency has been making similar moves on other fronts — modernising data platforms, deploying internal AI tools, consolidating submission portals. The direction of travel is clear.

For regulatory and quality operations teams, the planning question is not "when will we be inspected next." The planning question is "would our documentation hold up if an investigator walked in tomorrow with no advance notice and one day to look around." If the answer is anything less than yes, the time to fix it was last quarter.

It is now.